Week in Review: Taimei Raises $212 Million for AI Life Science Support Software

Deals and Financings • Taimei Technology of Shanghai completed a $212 million Series E/E+ round to expand its AI-based suite of clinical trial support software programs into other areas of drug R&D; • Ansun Biopharma of San Diego closed an $80 million Series B funding from China investors to develop its novel antiviral candidate; • dMed Biopharma, a Shanghai CRO that offers clinical trial services in China, the US and the EU, raised $50 million in a Series B financing; • Shaanxi Micot Technology completed a $16 million Pre-A financing to develop its portfolio of novel multi-targeted polypeptide drug candidates; • CanSino Biologics, a Tianjin vaccine company, filed to IPO on the Shanghai Star Board, six months after it completed a $161 Hong Kong initial offering; • Guangzhou Boji Medical Biotech, a CRO, formed a JV with Great Bay Bio of Hong Kong to develop a novel long-acting biologic for anemia; • Chengdu HitGen partnered with Galapagos NV to identify small molecule leads for Galapagos targets; Trials and Approvals • Japan's Eisai received China approval to launch Fycompa® in China as an adjunct treatment for partial onset epileptic seizures; • Shanghai's I-Mab Biopharma was authorized to conduct China Phase II/III trials of an anti-CD38 antibody for multiple myeloma; • Luqa Pharma of Shanghai announced China approval to market Lactéol®, a microbiome treatment for diarrhea in-licensed from Adare Pharma of France. Stock Symbols: (HK: 6185) (SHE: 300404) (Euronext: GLPG) (TSE: 4523)